Skip to content
Dose Brief
Menu
Head-to-head · Brief Score

Sesame Care vs GoodRx

Two GLP-1 desks, one scoreboard. We put Sesame Care and GoodRx head-to-head on the published Brief Score — the same six factors, scored the same way.

Higher Brief ScoreNo. 4 · Grade B+

Sesame Care

Visit Sesame Care Full brief →
vs
No. 105 · Grade C

GoodRx

Visit GoodRx Full brief →

The verdict

Sesame Care takes this head-to-head.

Sesame Care scores 87 to 72 on our six-factor Brief Score — An established national telehealth marketplace with the widest real brand-name GLP-1 access on the board — Wegovy (pen and pill), Zepbound, Ozempic and Mounjaro — plus provider-by-provider price transparency.

That doesn't make GoodRx a bad call — it's best for readers who want self-pay brand-name foundayo and zepbound kwikpen at retail pharmacies. Weigh the six factors below against your own priorities before you decide.

Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes the Brief Score.

Factor by factor

Both desks scored on the six published Brief Score factors. The higher score in each row is marked. See the methodology.

Price Stability
84
58
Supply Reliability
92
77
Transparency
94
68
Access Breadth
84
86
Clinical Oversight
80
68
Track Record
92
84
Sesame CareBrief Score 87 · 72GoodRx

Price, coverage & the tracker

Sesame CareGoodRx
Brief Score87/100 (B+)72/100 (C)
SemaglutideFrom $149/mo (brand Wegovy pill)Not disclosed
TirzepatideBrand Zepbound (price varies)From $299/mo (brand Zepbound)
CoverageNationwide marketplaceAll 50 states
Brand-name accessYesYes
Oral / sublingualYesInjection only
On the trackerStableprice stableNewnew to the tracker, no prior reading

Sesame Care: Marketplace pricing is set per provider rather than one desk rate; the brand-name Wegovy pill line held its ~$149 entry this cycle.

GoodRx: New to the tracker on 1 August 2026. The published line reads From $149/mo (brand Foundayo) at our first reading; there is no earlier reading of ours to compare it against yet.

Not sold on either?

CoreAge Rx tops the whole board at 94/100.

The steadiest desk on the board: one flat, no-step-up price on both molecules, nationwide, and it hasn't moved.

Keep comparing

Pricing, states and access reflect each provider's public disclosures at last review; the Brief Score is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.